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ARTICLE
Association study between the rs165599 
catechol-O-methyltransferase genetic 
polymorphism and schizophrenia in a 
Brazilian sample
Estudo de associação entre o polimorfismo genético rs165599 da catecol-O-metiltransferase 
e esquizofrenia em uma amostra brasileira
Quirino Cordeiro1, Renata Teixeira da Silva1, Homero Vallada2
Schizophrenia is a severe psychiatric disorder character-
ized by psychotic symptoms and functional impairment, with 
recurrent relapses and continuing disability. The risk factors 
for schizophrenia are indicators currently perceived as epiphe-
nomena of pathophysiological processes resulting from gene-
environment interactions that remain poorly understood1.
Widespread impairments in brain function and structure 
have been shown in schizophrenia cases. It is also clear that, 
to a lesser degree, unaffected family members share many of 
the neurobiological abnormalities found in affected individu-
als, which suggests that the alleles that underlie the genetic 
risk of schizophrenia may primarily exert their effects on in-
termediate traits such as cerebral structure or function1.
Although the etiology of schizophrenia is not well estab-
lished yet, data from many studies have shown that genetic 
load alone cannot determine development of schizophrenia, 
thus favoring an additive model of interactive genetic and en-
vironmental risk factors. This gene-environment interaction 
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ABSTRACT
Schizophrenia is a severe psychiatric disorder with frequent recurrent psychotic relapses and progressive functional impairment. It results 
from a poorly understood gene-environment interaction. The gene encoding catechol-O-methyltransferase (COMT) is a likely candidate for 
schizophrenia. Its rs165599 (A/G) polymorphism has been shown to be associated with alteration of COMT gene expression. Therefore, the 
present study aimed to investigate a possible association between schizophrenia and this polymorphism. The distribution of the alleles and 
genotypes of this polymorphism was investigated in a Brazilian sample of 245 patients and 834 controls. The genotypic frequencies were in 
Hardy-Weinberg equilibrium and no statistically significant differences were found between cases and controls when analyzed according to 
gender or schizophrenia subtypes. There was also no difference in homozygosis between cases and controls. Thus, in the sample studied, there 
was no evidence of any association between schizophrenia and rs165599 (A/G) polymorphism in the non-coding region 3’ of the COMT gene.
Key words: enzyme, genetics, psychosis, schizophrenia.
RESUMO
A esquizofrenia é um grave transtorno psiquiátrico que apresenta freqüentes recorrências psicóticas e incapacitação progressiva. Resulta de 
uma interação gene-ambiente ainda pouco compreendida. O gene da catecol-O-metiltransferase (COMT) é considerado um possível candidato 
para esquizofrenia. O polimorfismo genético rs165599 (A/G) da COMT foi associado com alteração da expressão do seu gene. Assim, o presente 
trabalho tem como objetivo investigar a possível associação de tal polimorfismo com esquizofrenia. A distribuição de seus alelos e genótipos 
foi investigada em uma amostra brasileira composta de 245 pacientes e 834 controles. As frequências genotípicas estavam em equilíbrio de 
Hardy-Weinberg e não se encontrou diferença estatisticamente significante entre casos e controles, quando analisados por gênero e subtipos 
da esquizofrenia. Não houve também diferença de homozigosidade entre casos e controles. Desse modo, na amostra estudada, não houve 
evidência de associação entre esquizofrenia e o polimorfismo rs165599 (A/G) localizado na região 3’ não codificadora do gene da COMT.
Palavras-Chave: enzima, genética, psicose, esquizofrenia.
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might occur at specific stages of development of occurrences 
of this disorder1.
Genetic epidemiological investigations have suggested 
that there is a genetic component with significant participa-
tion in the etiology of schizophrenia, and heritability estimates 
as high as 80% have been reported1. The mode of inheritance 
is complex, with polygenic environmental interaction. The role 
of single relevant genes must be small, and therefore associa-
tion studies involving case-control approaches have been con-
ducted to evaluate the allelic variations of specific candidate 
genes that may be related to the etiopathology of the disorder1.
Some of the most investigated genes in studies on vulnera-
bility to schizophrenia are those that code for proteins of  the 
dopaminergic system, because of evidence of the role of cen-
tral dopamine pathways in the pathophysiology of the disor-
der. Therefore, the genes involved in the dopaminergic system 
are potential targets for genetic association investigations in 
schizophrenia. Polymorphisms in dopamine transporter and 
receptors genes have been widely investigated as risk factors 
for schizophrenia development, but the results have been in-
conclusive2-5. Thus, other possible candidates for such inves-
tigations are the enzymes that metabolize dopamine, such as 
catechol-O-methyltransferase (COMT).
The gene encoding the enzyme COMT has been consid-
ered to be a likely candidate for an association with schizophre-
nia. Most COMT genetic association studies have focused on a 
particular single nucleotide polymorphism (SNP) that results in 
a change from valine to methionine at codon 158/108 (rs4680). 
It has been suggested that this may contribute towards increased 
prefrontal catabolism and impaired prefrontal cortex function6.
Another interesting polymorphism of the COMT gene is 
rs165599 (A/G), which is located in the 3’ untranslated region 
of the COMT gene, close to exon 1. Its G allele was first shown 
to be highly associated with schizophrenia in Ashkenazi Jews 
by Shifman et al., as a component of a haplotype (G-G-G hap-
lotype of three SNPs: rs737865, rs4680 and rs165599) of the 
COMT gene7. This haplotype has also been reported to be 
linked with lower expression of COMT mRNA in the human 
brain7. In a postmortem study, Bray et al. demonstrated that 
this polymorphism altered COMT gene expression, which 
was less expressed when the G allele was present8.
On the other hand, Okochi et al. conducted a meta-anal-
ysis study in which no clear association between COMT 
genotypes and schizophrenia was found9. However, some 
studies have found associations between rs165599 (A/G) 
COMT genetic polymorphism and different clinical aspects 
of schizophrenia. Gu et al. showed an association between 
the polymorphism investigated and violent behavior in a 
sample of Chinese male schizophrenic patients10.
In a study conducted on a Taiwanese sample, the A al-
lele of rs165599 COMT polymorphism was transmitted pref-
erentially to the affected individuals, and was significant-
ly associated with later age of onset, greater severity of the 
delusion/hallucination symptom dimension and poorer 
performance of neurocognitive functioning11. Studying tar-
dive dyskinesia, in a sample of schizophrenia/schizoaffec-
tive disorder patients, Zai et al. found a significant associ-
ation between the marker rs165599 in the 3’ untranslated 
region of COMT and this clinical condition12.
Thus, since schizophrenia is a mental disorder with dif-
ferent clinical phenotypes, and despite the negative findings 
from meta-analyses that investigated the association between 
rs165599 catechol-O-methyltransferase genetic polymor-
phism and schizophrenia, several studies have found associa-
tions of this polymorphism with different clinical features of 
the disorder.
Taking this into account, we conducted a study with the 
aims of investigating a possible association between A/G COMT 
polymorphism in the non-coding region 3’ (rs165599) and 
schizophrenia, and also investigating different aspects of the 
disorder, such as schizophrenia subtypes and gender. We also 
examined whether there was any association between homo-
zygosity of the polymorphism investigated and schizophrenia.
METHODS
Sample
The sample was composed of 245 Brazilian patients di-
agnosed with schizophrenia and 834 sex and age-matched 
control subjects recruited at the Institute of Psychiatry, 
University of São Paulo Medical School. Schizophrenia was 
diagnosed in accordance with the DSM-IV criteria, based 
on clinical interviews conducted by psychiatrists. The 834 
healthy control subjects were selected at the Blood Donation 
Unit at the University of São Paulo Medical School.
All the patients and control subjects provided written in-
formed consent for taking blood samples. Approval for the 
study was obtained from the local Ethics Committee.
DNA extraction
A blood sample of 20 ml was drawn from each participant 
in the study, and DNA was extracted from leukocytes using 
the “salting out” protocol13.
Genotyping
Genotyping was performed under contract by Prevention 
Genetics (USA) (www.preventiongenetics.com). The poly-
morphism investigated was genotyped blind to the individu-
als’ clinical status.
Statistical analysis
The statistical power of the sample was evaluated us-
ing the CaTS software (Center for Statistical Genetics, 
University of Michigan; http://www.sph.umich.edu/csg/
abecasis/CaTS/index.html). A test for deviations from 
Hardy-Weinberg equilibrium was performed using the 
HWE program14.
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The chi-square test was used to investigate possible asso-
ciations shown by genotypes and alleles with schizophrenia 
and to assess differences between gender and schizophrenia 
subtype distributions in both patient and control groups. The 
analyses were performed using Epi-Info version 6.0.
For all statistical tests, the significance level was set at 
α<0.05 or 5%.
RESULTS
The sample size power was calculated to be 80% under 
the following conditions: 200 patients, 400 control subjects, 
disorder prevalence of 1%, average allelic frequency of 30%, 
significance level of 0.05 and increased susceptibility towards 
developing the disorder, of 1.5 for the allele (OR=1.5). If the 
numbers of patients and control subjects became 245 and 
829 respectively, i.e. the number of individuals in the present 
study, the sample size power would rise to 91%.
For Hardy-Weinberg equilibrium analysis, the actual gen-
otype frequencies were compared with Hardy-Weinberg-
based expected genotype frequencies. In both groups (cases: 
p=0.94; controls: p=0.43), the genotype frequencies were in 
Hardy-Weinberg equilibrium.
According to our analysis, no statistically significant 
differences in the distribution of allelic and genotypic fre-
quencies between the groups of patients and controls were 
observed (Table 1). Taking into consideration the data sug-
gesting that schizophrenia is a heterogeneous disorder, we 
also repeated our analyses with division of our sample accord-
ing to the current most important schizophrenia subtypes 
(paranoid and disorganized) (Tables 2 and 3). Furthermore, 
the patients and controls were also investigated according 
to gender, since some studies have suggested that there are 
differences in the clinical manifestation of schizophrenia ac-
cording to the patients’ gender (Table 4). Likewise, the sam-
ples were also studied in order to ascertain whether homozy-
gosity of the polymorphism investigated could be associated 
with schizophrenia in our sample (Table 5). However, we did 
not find any significant associations when the analysis was 
conducted using the phenotypic variables described above.
Table 3. Distribution of the genotypes and alleles of rs165599 
genetic polymorphism of catechol-O-methyltransferase, 
according to schizophrenia subtype (disorganized subtype).
Polymorphism Cases (%) Controls (%) χ2 d.f. p-value
GENOTYPES
    A/A 15 (28.3) 257 (31)
0.2 2 0.9    A/G 27 (50.95) 399 (48.13)
    G/G 11 (20.75) 173 (20.87)
    Total 53 (100) 829 (100)
ALLELES
    A 57 (53.77) 913 (55.07)
0.07 1 0.79
    G 49 (46.23) 745 (44.93)
    Total 106 (100) 1658 (100)
Table 2. Distribution of the genotypes and alleles of rs165599 
genetic polymorphism of catechol-O-methyltransferase, 
according to schizophrenia subtype (paranoid subtype).
Polymorphism Cases (%) Controls (%) χ2 d.f. p-value
GENOTYPE
    A/A 49 (28.99) 257 (31)
0.27 2 0.87    A/G 84 (49.71) 399 (48.13)
    G/G 36 (21.3) 173 (20.87)
    Total 169 (100) 829 (100)
ALLELES
    A 182 (53.85) 913 (55.07)
0.17 1 0.68
    G 156 (46.15) 745 (44.93)
    Total 338 (100) 1658 (100)
d.f: degree of freedom
d.f: degree of freedom
Table 4. Distribution of the genotypes and alleles of rs165599 
genetic polymorphism of catechol-O-methyltransferase 
between patients and controls, according to gender.
Male
Polymorphism Cases (%) Controls (%) χ2 d.f p-value
GENOTYPE
    A/A 49 (30.82) 161 (31.14)
    A/G 75 (47.17) 245 (47.39) 0.03 2 0.98
    G/G 35 (22.01) 111 (21.47)
    Total 159 (100) 517 (100)
ALLELE
    A 173 (54.4) 567 (54.84)
    G 145 (45.6) 467 (45.16) 0.02 1 0.88
    Total 318 (100) 1034 (100)
Female
Polymorphism Cases (%) Controls (%) χ2 d.f p-value
GENOTYPE
    A/A 24 (27.91) 96 (30.77)
    A/G 47 (54.65) 155 (49.68) 0.66 2 0.71
    G/G 15 (17.44) 61 (19.55)
    Total 86 (100) 312 (100)
ALLELE
    A 95 (55,23) 347 (55.61)
    G 77 (44,77) 277 (44.39) 0.00 1 0.95
    Total 172 (100) 624 (100)
d.f: degree of freedom
Table 5. Distribution of the genotypes and alleles of rs165599 genetic 
polymorphism of catechol-O-methyltransferase for homozygosis.
Polymorphism Cases (%) Controls (%) χ2 d.f. p-value
GENOTYPES
    AA/+G/G 123 (50.2) 430 (51.87)
0.21 1 0.64
    A/G 122 (49.8) 399 (48.13)
    Total 245 (100) 829 (100)
d.f: degree of freedom
Table 1. Distribution of the genotypes and alleles of rs165599 
genetic polymorphism of catechol-O-methyltransferase 
between patients and controls.
Polymorphism Cases (%) Controls (%) χ2 d.f. p-value
GENOTYPE
    A/A 73 (29.79) 257 (31)
0.22 2 0.89    A/G 122 (49.8) 400 (48.25)
    G/G 50 (20.41) 172 (20.75)
    Total 245 (100) 829 (100)
ALLELE
    A 268 (54.69) 914 (55.13)
0.02 1 0.88
    G 222 (45.31) 744 (44.87)
    Total 490 (100) 1658 (100)
d.f: degree of freedom
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DISCUSSION
In the present investigation, we tested the association 
between rs165599 A/G COMT genetic polymorphism and 
schizophrenia in a Brazilian sample of 245 patients (159 
males and 86 females) and 829 healthy controls (565 males 
and 264 females). Despite previous investigations, our study 
is, to the best of our knowledge, the first association study an-
alyzing this polymorphism in a Brazilian sample of patients 
with schizophrenia. However, we did not find any association 
between the polymorphism investigated and schizophrenia.
As mentioned above, we also conducted analyses dividing 
the sample according to the current most important schizo-
phrenia subtypes: paranoid and disorganized. However, we did 
not find any significant association when the analysis was con-
ducted using the phenotypic variables described above.
The patients and controls were also investigated according 
to gender, since some studies have suggested that there may 
be differences in age of onset and clinical prognosis according 
to the patients’ gender15. No difference whatsoever was found.
We have tested whether there was any association between 
homozygosity and schizophrenia. There have been some re-
ports showing associations between homozygosity of other 
genetic polymorphisms, like Ser9Gly of the dopamine receptor 
subtype 3 (DRD3), and schizophrenia16. This type of associa-
tion may represent an advantage for heterozygosity, probably 
because the presence of two different molecular forms of the 
neurotransmitter receptor, thereby resulting in an increased 
ability to respond adaptively to variations in the environment, 
happening either during neural development or in adulthood. 
However, in our sample, we did not find any such association.
According to our analysis, no statistically significant differenc-
es in the distribution of allelic and genotypic frequencies between 
the groups of patients and controls were observed, even when we 
stratified the sample according to gender and schizophrenia sub-
type. Furthermore, no significant association was found when we 
investigated a possible association between homozygosity of the 
polymorphism investigated and schizophrenia.
One possible limitation of the present study may relate 
to population stratification, especially because the Brazilian 
population is not ethnically homogeneous, which may lead to 
lower power to detect associations. In populations with highly 
admixed ethnicity like in Brazil, problems regarding ethnic strat-
ification may be faced. Since physical phenotype in Brazil is not 
an adequate predictor of genomic ancestry, ethnical matching 
in case-control studies is rendered difficult17,18,19. However, the 
present sample (patients and controls) was in Hardy-Weinberg 
equilibrium, which indicates that our sample may not have had 
any important problems regarding population stratification20.
In conclusion, the results from the present study do not pro-
vide evidence for any association between A/G COMT polymor-
phism in the non-coding region 3’ (165599) and schizophrenia, 
in the sample investigated. This finding is in accordance with 
a recent published meta-analysis. However, further studies on 
this particular polymorphism in relation to schizophrenia are 
still needed, especially with regard to investigating the different 
clinical features of the disorder. Investigations in samples with 
different ethnic backgrounds must be carried out as well.
